Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CD4-IgG2 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| CD4-IgG2 (PRO 542) | DRUG | - |
Inclusion Criteria: * Confirmed diagnosis of HIV * Patients must be on a stable dose of acceptable anti-HIV therapy or receiving no anti-HIV therapy for at least four (4) weeks prior to the start of this study * HIV-1 determination by RNA-PCR greater than or equal to 100,000 copies/ml * CD4 count \...
Top 20 of 28 competitors
CD4-IgG2 is an investigational small molecule being studied for the treatment of HIV infections. It is in Phase 2 clinical development, with one completed trial evaluating its safety and efficacy in HIV-infected patients. The drug is not approved and remains under investigation.
CD4-IgG2 is being developed by Lantheus Holdings, Inc., a company traded on the NASDAQ under the ticker symbol LNTH. The drug is currently in Phase 2 clinical development for HIV infections.
CD4-IgG2 is in Phase 2 clinical development. It is an investigational drug for HIV infections and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and the drug remains under clinical investigation.
CD4-IgG2 has one completed clinical trial, NCT00055185, titled "Safety and Efficacy of PRO 542 in the Treatment of HIV-Infected Patients." This Phase 2 study enrolled 24 participants in the United States and evaluated the drug in patients with HIV infections and AIDS.
Yes, CD4-IgG2 is also known as PRO 542. The completed clinical trial NCT00055185 refers to the drug as PRO 542, confirming that both names refer to the same investigational therapy for HIV infections.